Pharmacokinetic characteristics of piperacillin/tazobactam

@article{Sorgel2005PharmacokineticCO,
  title={Pharmacokinetic characteristics of piperacillin/tazobactam},
  author={Fritz Sörgel and Martina Kinzig},
  journal={Intensive Care Medicine},
  year={2005},
  volume={20},
  pages={S14-S20}
}
Piperacillin/tazobactam is a new combination of a broad-spectrum penicillin and a beta-lactamase inhibitor. In studies in healthy volunteers, the pharmacokinetics of piperacillin combined with tazobactam were similar to those of piperacillin alone. In contrast, tazobactam administered with piperacillin achieved higher plasma concentrations and had a longer half-life than tazobactam administered alone. Intravenous infusion of 4.0 g piperacillin with 0.5 g tazobactam over 5 min resulted in mean… 

Pharmacokinetic evaluation of piperacillin-tazobactam

Alternative dosing regimens, which may include administration by extended or continuous infusion of piperacillin-tazobactam as a mechanism to increase the likelihood of pharmacodynamic target attainment, are described.

Population Pharmacokinetics of Piperacillin at Two Dose Levels: Influence of Nonlinear Pharmacokinetics on the Pharmacodynamic Profile

While renal elimination of piperacillin was saturable at therapeutic concentrations, the extent of saturation of nonrenal clearance was small and the influence of saturable elimination on PTAs for clinically relevant dosage regimens was relatively small.

Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses

Simulations showed that continuous or extended infusion methods performed better than intermittent administration to achieve appropriate pharmacodynamic targets, and pharmacokinetic elements for piperacillin-tazobactam in an intensive care unit setting were synthesized.

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.

Intermittent infusion and continuous infusion of piperacillin and tazobactam provided sufficient drug exposure to treat those pathogens commonly implicated in intra-abdominal infections.

Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination

Clinical trials have demonstrated piperacillin–tazobactam to be effective for the treatment of patients with intra-abdominal infections, skin and soft tissue infections, lower respiratory tract infections, complicated urinary tract infections and gynecological infections and more recently, febrile neutropenia.

A Pharmacokinetic Analysis of Continuously Infused Piperacillin/Tazobactam in Critically Ill Trauma Patients

Although the authors found a wide variability in serum piperacillin/tazobactam concentrations, the administration of a 16/2 g per day dose as a continuous infusion achieves optimal pharmacokinetic parameters for commonly isolated microorganisms in critically ill trauma patients.

Concentrations of piperacillin-tazobactam in human jaw and hip bone.

The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF)

It is suggested that prolonged SLED-HDF (12 h) will only maintain a sufficient meropenem and piperacillin-tazobactam plasma concentration to achieve a target of fT >  MIC for gram-negative pathogens for less than 40% of the time.

Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection

The doses of ceftolozane/tazobactam simulated were highly effective in reducing the bacterial load of E. coli but less so for K. pneumoniae (MIC 4 mg/L) and meropenem produced an overall greater reduction in pathogen load.

References

SHOWING 1-10 OF 32 REFERENCES

Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin.

The pharmacokinetics of tazobactam administered intravenously alone were compared with the pharmacokinetically coadministered with piperacillin, and the penetration into an inflammatory exudate in six healthy males was studied.

Single‐dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease

The pharmacokinetics of piperacillin and tazobactam were evaluated in eight normal volunteers and in 52 patients with renal dysfunction, and total body clearance, area under the curve, and terminal elimination rate correlated with renal function.

Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery

In plasma and in all investigated tissues, piperacillin as well as tazobactam reached or exceeded the concentrations found to be effective in vitro, with a peak in concentration at between 1 and 2 h after the start of infusion followed by a decline of concentrations that were almost parallel to the curves of the drug concentrations in plasma.

Comparative pharmacokinetics of apalcillin and piperacillin

The pharmacokinetics of apalcillin and piperacillin, each administered intravenously as a single 2-g dose, were compared in 10 volunteers in a randomized study of crossover design using bioassay and

Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli

Combination treatment of piperacillin combined with tazobactam in experimental meningitis resulted in significantly better bactericidal activity in the cerebrospinal fluid.

The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.

The tissue concentrations of piperacillin and tazobactam and their pharmacokinetic profiles in plasma and tissues encourage the view that the synergy observed in vitro will be reflected in clinical use.

Human pharmacodynamics of beta-lactams, aminoglycosides and their combination.

  • G. Drusano
  • Biology, Medicine
    Scandinavian journal of infectious diseases. Supplementum
  • 1990
In-vitro and animal model data indicate that the time beta-lactam serum concentrations remain above the MIC is an important determinant of the organism kill at the primary infection site and area under the curve and peak concentrations have been linked to organism kill and suppression of resistance.

Efficacy and safety of aminoglycosides once-a-day: experimental and clinical data.

  • P. Tulkens
  • Medicine, Biology
    Scandinavian journal of infectious diseases. Supplementum
  • 1990
In vitro and animal data show that the efficacy of an aminoglycoside is primarily related to its serum peak levels and AUC, whereas its toxicity is critically dependent upon the schedule of the

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate

For relatively susceptible strains of members of the family Enterobacteriaceae, neither combination was predictably more active than the other, but relatively resistant strains were generally more susceptible to piperacillin-tazobactam.

Piperacillin/tazobactam in the treatment of serious acute soft tissue infection.

The tazobactam/piperacillin combination is suitable for the treatment of serious soft tissue infection, but increased doses may be appropriate in infection at poorly perfused sites.